Ben Bredeson

Left Guard

Age: 27
Free Agency: 2028 (Void)
Accrued Seasons: 5
  • 2025 Salary Cap Charge: $2,436,000 (0.86% of cap)
  • 2025 Cash Payout: $7,500,000 (2.70% of spending)
  • 2025 Cash to Cap Ratio: 3.08
  • Contract Value: $22,000,000 ($7,333,333 APY)
  • Fully Guaranteed Money: $12,500,000
  • Contract Ranking: 13/87 at LG

Current Contract

(UFA, signed 2025)
(📝: indicates contract trigger occuring during that year)
YearAgeBase SalaryProrated Signing BonusRoster BonusGuaranteed SalaryCap
Number
Cap %
Dead Money & Cap Savings
202527$1,170,000$1,266,000$6,330,000$1,170,000$2,436,0000.9%
202628$7,500,000$1,266,000$0$5,000,000$8,766,0003.0%
2027 📝
March 18: Roster bonus due
29$6,500,000$1,266,000$500,000$0$8,266,0002.7%
2028 📝
March 11: Contract voids
30Void$1,266,000VoidVoid$2,532,000--
202931Void$1,266,000VoidVoid$0--
Total$15,170,000$6,330,000$6,830,000$6,170,000$22,000,000

Contract Notes

Ben Bredeson signed a 3 year contract with the Tampa Bay Buccaneers worth $22 million with $12.5 million guaranteed. There are two void years in the contract for salary cap purposes. The final contract year is an option year that the team can pick up on the last day of the 2026 league year.

Cash Flows

- fully earned money
- unearned or partially earned money
$7.3M
$14.7M
$22M
202520262027
Cash Due$7,500,000$7,500,000$7,000,000
Running Cash$7,500,000$15,000,000$22,000,000
Career Earnings: $7,289,400
Career APY: $1,457,880
Potential Earnings: $29,289,400
Total Guarantees: $15,238,800
Largest Cash Payment: $7,500,000 (2025)
Largest Cap Number: $8,766,000 (2026)

Contract History

TeamContract TypeStatusYear SignedYrsTotalAPYGuaranteesAmount Earned% EarnedEffective APY
RavensDraftedTraded20204$3,789,400$947,350$494,400$1,104,40029.1%$1,104,400
GiantsDraftedExpired20204$3,789,400$947,350$494,400$2,685,00070.9%$895,000
BuccaneersUFAExpired20241$3,000,000$3,000,000$1,750,000$3,500,000116.7%$3,500,000
BuccaneersUFAActive20253$22,000,000$7,333,333$12,500,000$00.0%$0
Earnings By Team
TeamYrsSalaryAPYPaid on Cap% Paid on CapPaid as Dead Money% Paid as Dead Money
Ravens1$1,104,400$1,104,400$733,6000.0%$370,8000.0%
Giants3$2,685,000$895,000$2,685,0000.0%$00.0%
Buccaneers1$3,500,000$3,500,000$3,000,0000.0%$00.0%

Season History

YearTeamBase SalaryProrated BonusRoster BonusPer Game Roster BonusGuaranteed SalaryCap
Number
Cap %Cash Paid
2020Ravens$610,000$123,600$0$0$0$733,6000.4%$1,104,400
2021Giants$780,000$0$0$0$0$780,0000.4%$780,000
2022Giants$895,000$0$0$0$0$895,0000.4%$895,000
2023Giants$1,010,000$0$0$0$0$1,010,0000.4%$1,010,000
2024Buccaneers$1,660,000$0$1,000,000$340,000$1,750,000$3,000,0001.2%$3,500,000
2025Buccaneers$1,170,000$1,266,000$6,330,000$0$1,170,000$2,436,0000.9%$7,500,000
2026Buccaneers$7,500,000$1,266,000$0$0$5,000,000$8,766,0003.0%$7,500,000
2027Buccaneers$6,500,000$1,266,000$500,000$0$0$8,266,0002.7%$7,000,000
2028Buccaneers$1,390,000$1,266,000$0$0$0$2,532,000--$0
2029Buccaneers$1,435,000$1,266,000$0$0$0$0--$0
Total$22,950,000$6,453,600$7,830,000$340,000$7,920,000$28,418,600$29,289,400
Dead Money History
TeamYearCap ChargeCash Paid
Ravens2021$123,600$0
Ravens2022$247,200$0
Total$370,800$0

Statistics

YearGames PlayedGames InactiveSnaps
InjuredHealthyOffenseSpecial
202010064.8%8.1%
202185026.7%0.7%
2022110047.7%9.6%
2023161091.8%11.1%
2024170098.8%18.4%

Valuation Diamond

The diamond is a scatterplot graph that visualizes the relation of the player's APY (in green) and performance (in blue, as measured by OTC's Valuations) to the rest of the league at his position. To understand how to read the diamond, read this explainer.

OTC ValuationAPY
Regular$7,384,000$7,333,333
Injury Adjusted$7,384,000$7,333,333
test
OTC Valuation $2.4M $4.8M $7.2M $9.6M $11.9M APY $3.5M $7M $10.5M $14M $17.5M $6,149,000 $4,918,330

Weekly Valuation Trends

The chart below illustrates the trend of the player's weekly OTC Valuations (in blue) from the most recent season, using APY (in green) and, if applicable, cash that is due to the player in the next season (in red) as benchmarks. Weeks not plotted indicate that the player was inactive or on a bye.

To see interactive and more in-depth use of OTC Valuation data, subscribe to OTC Premium.